Sigmoidoscope Market By Product Type (Flexible Sigmoidoscopes, Rigid Sigmoidoscopes), By Usage (Reusable, Disposable), By Application (Diagnostic, Screening, Therapeutic), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Diagnostic Centers), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Sigmoidoscope Market: Expanding Role in Targeted Lower-GI Diagnosis, Digital Point-of-Care Visualization, Surveillance, and Endoscopy Capacity Optimization

The Global Sigmoidoscope Market was valued at USD 1.62 billion in 2025 and is projected to reach USD 2.37 billion by 2032, expanding at a CAGR of 5.6% during 2026–2032.

 

A sigmoidoscope is a medical viewing instrument used to examine the rectum and sigmoid colon, which form the lower portion of the large intestine. It typically contains a light and imaging system that allows physicians to inspect the bowel lining for abnormalities.

 

Two main types are used. Flexible sigmoidoscopes have a bendable insertion tube that can move through the lower colon more easily and are commonly preferred in modern practice. Rigid sigmoidoscopes are straight instruments used mainly for selected rectal examinations.

 

Sigmoidoscopy can help investigate rectal bleeding, abdominal discomfort, changes in bowel habits, inflammation, ulcers, polyps, and possible colorectal cancer. The procedure can also be used to obtain tissue biopsies or remove certain small polyps.

 

What Technological Advancements Are Improving Sigmoidoscopy?

Recent development is focused on improving visualization, lesion detection, patient comfort, and infection control.

• Artificial Intelligence and CADe: AI-based computer-aided detection systems can analyze endoscopic images in real time and help identify small, flat, or difficult-to-see polyps and adenomas.
• Image-Enhanced Endoscopy: Digital contrast and advanced optical technologies improve visualization of mucosal and blood-vessel patterns, supporting better identification of abnormal tissue.
• High-Definition Imaging: Improved camera sensors provide clearer views of the lower gastrointestinal tract and may support more accurate diagnosis.
• Disposable and Slimmer Designs: Single-use components and increasingly compact flexible systems can reduce reprocessing concerns while improving handling and patient comfort.
• Self-Propelled and Soft Robotic Systems: Emerging robotic concepts aim to move through the bowel with less external force, potentially reducing discomfort and dependence on sedation.

Flexible sigmoidoscopy is also increasingly considered alongside non-invasive screening methods such as the fecal immunochemical test (FIT), allowing healthcare providers to combine stool-based screening with targeted endoscopic examination when appropriate.

These advances are supporting the sigmoidoscope market by increasing demand for AI-enabled imaging, high-definition visualization, disposable technologies, and more patient-friendly endoscopic systems.

 

What is creating commercial demand beyond routine colorectal screening?

The strongest demand opportunity is increasingly linked to targeted lower-GI diagnosis and surveillance rather than population screening alone. Flexible sigmoidoscopy is used when clinicians need direct visualization for rectal bleeding, bowel-habit changes, abdominal symptoms, suspected polyps, inflammatory changes, and other lower-colon abnormalities. It can also support biopsy or removal of selected polyps, creating procedure demand from symptomatic referrals and specialist gastrointestinal or colorectal pathways.

Specialty care adds recurring utilization. Flexible sigmoidoscopy is used in the assessment and surveillance of conditions such as ulcerative colitis and proctitis, while digital systems are extending focused examinations into outpatient workflows. For example, SurgEase positions LumenEye X1 for anorectal imaging, biopsy, cancer-resection planning, anastomosis monitoring, ileal-pouch surveillance, and inflammatory bowel disease assessment. These applications increase demand for systems offering rapid setup, image capture, repeat surveillance, and the ability to perform selected examinations outside conventional endoscopy rooms.

 

How are colorectal screening trends reshaping the addressable market?

The U.S. colorectal screening population is large, although screening growth does not translate equally into sigmoidoscope demand. CDC analysis of the 2023 National Health Interview Survey found that 67.4% of adults aged 45–75 were up to date with colorectal cancer screening, compared with only 37.1% among adults aged 45–49 and 73.4% among adults aged 50–75. Colonoscopy within the previous 10 years was reported by 53.4% of adults aged 45–75.

Clinician preference also influences modality demand. A CDC-published national survey found that 98.9% of primary care clinicians and 100% of gastroenterologists routinely recommended colonoscopy, compared with 34.6% and 30.2%, respectively, for flexible sigmoidoscopy. This has shifted the commercial role of sigmoidoscopy toward focused lower-GI diagnosis, specialist surveillance, and procedures in which full colonoscopy is not required.

England demonstrates a similar transition. The former bowel-scope screening pathway based on flexible sigmoidoscopy was decommissioned as national screening moved toward expanded fecal immunochemical testing. As a result, current sigmoidoscope demand is increasingly concentrated in diagnostic, surveillance, colorectal-surgery, and specialist outpatient pathways rather than routine population screening.

 

What do current procedure volumes reveal about endoscopy capacity?

NHS England reported 14,416 flexible sigmoidoscopy procedures in December 2025, compared with 15,381 in December 2024, representing a 6.3% year-over-year decline. Year-to-date activity reached 135,226 procedures in 2025/26 compared with 152,713 in 2024/25.

At the same time, the flexible sigmoidoscopy waiting list increased from 21,482 to 22,764 patients, or 6.0%. In December 2025, 32.3% of patients awaiting flexible sigmoidoscopy had waited six weeks or longer, compared with 27.8% one year earlier.

These capacity pressures create demand for equipment that can increase procedure availability, decentralize suitable examinations, improve room utilization, and move selected lower-rectal procedures into outpatient colorectal services. Device purchasing is therefore increasingly influenced by workflow productivity, procedure turnaround, staffing requirements, and site-of-care flexibility.

 

How do reimbursement and procurement support sigmoidoscope utilization?

U.S. reimbursement provides an established pathway for eligible procedures. Medicare Part B covers screening flexible sigmoidoscopy once every 48 or 120 months depending on patient risk and previous screening history. Continued coverage maintains a reimbursable procedure base, even as colonoscopy and stool-based screening account for a larger share of routine colorectal screening.

Australia similarly maintains reimbursement for clinically indicated procedures. MBS item 32084 covers sigmoidoscopy or colonoscopy up to the hepatic flexure, with or without biopsy. Australia's National Bowel Cancer Screening Program primarily uses immunochemical fecal occult blood testing, with screening kits mailed every two years to eligible people aged 50–74 and available on request to people aged 45–49 since July 2024. Sigmoidoscope demand therefore remains more closely linked to diagnostic and specialist procedures following initial assessment.

Procurement activity also illustrates the recurring-revenue potential of accessories. A UK contract awarded in May 2025 covered three LumenEye X1 endoscopes together with ongoing supplies of endoscope cover sheaths. This model combines initial equipment revenue with continuing procedure-linked consumable sales.

 

What Defines Demand and Adoption Patterns Across the Sigmoidoscope Market?

Product type influence on market demand

Flexible Sigmoidoscopes accounted for an estimated 76.0% market share, equivalent to approximately USD 1.23 billion in 2025, and are projected to expand at an estimated CAGR of 6.1%. Their leading position is supported by greater maneuverability, improved visualization of the distal colon, compatibility with biopsy and therapeutic accessories, and integration with modern video endoscopy systems used across hospitals and specialist gastrointestinal settings.

Rigid Sigmoidoscopes represented an estimated 24.0% share, valued at approximately USD 0.39 billion in 2025, and are expected to grow at an estimated CAGR of 3.9%. Demand remains concentrated in focused rectal and lower-bowel examinations where direct access, procedural simplicity, durability, and established use in colorectal and proctology practices remain important.

Impact of usage type on purchasing patterns

Reusable Sigmoidoscopes held an estimated 72.0% market share, representing approximately USD 1.17 billion in 2025, and are projected to grow at an estimated CAGR of 5.0%. Their dominance is supported by established hospital endoscopy infrastructure, repeated use across high procedure volumes, compatibility with existing processors, and the ability to distribute acquisition costs over a large number of examinations.

Disposable Sigmoidoscopes accounted for an estimated 28.0% market share, valued at approximately USD 0.45 billion in 2025, and are projected to record the faster estimated CAGR of 7.1%. Growth is supported by demand for simplified procedure preparation, reduced dependence on reusable-device reprocessing, faster turnaround, and greater flexibility across outpatient and decentralized examination settings.

 

Applications accounting for the largest sigmoidoscope demand

Diagnostic applications represented the largest segment with an estimated 47.0% market share, equivalent to approximately USD 0.76 billion in 2025, and are expected to grow at an estimated CAGR of 5.2%. Demand is driven by lower-GI examinations for bleeding, bowel changes, suspected polyps, inflammation, and other abnormalities requiring direct visualization and, where needed, tissue sampling.

Screening applications accounted for an estimated 34.0% market share, valued at approximately USD 0.55 billion in 2025, and are projected to expand at an estimated CAGR of 6.1%. Although colonoscopy and stool-based tests hold a stronger position in many national screening pathways, sigmoidoscopy continues to contribute to selected colorectal screening programs, follow-up pathways, and targeted examination of the distal colon.

Therapeutic applications represented an estimated 19.0% share, equivalent to approximately USD 0.31 billion in 2025, and are expected to grow at an estimated CAGR of 5.7%. Growth is supported by procedures involving biopsy, selected polyp removal, post-surgical assessment, and other lower-GI interventions where visualization and treatment can be combined within the same procedure.

 

End Users Generating the Largest Share of Sigmoidoscope Revenue

Hospitals accounted for the largest estimated share at 46.0%, representing approximately USD 0.75 billion in 2025, and are projected to grow at an estimated CAGR of 5.1%. Their leading position reflects large diagnostic and therapeutic procedure volumes, established endoscopy departments, imaging infrastructure, reprocessing capabilities, and greater ability to invest in advanced reusable systems.

Ambulatory Surgical Centers represented an estimated 20.0% market share, valued at approximately USD 0.32 billion in 2025, and are projected to record the fastest end-user growth at an estimated CAGR of 6.4%. Demand is increasing as outpatient facilities seek shorter procedure cycles, efficient room utilization, lower infrastructure costs, and devices suited to same-day gastrointestinal and colorectal procedures.

Specialty Clinics accounted for an estimated 21.0% share, equivalent to approximately USD 0.34 billion in 2025, and are expected to expand at an estimated CAGR of 5.7%. Colorectal, gastroenterology, and proctology clinics increasingly favor focused and portable visualization systems that allow selected lower-bowel examinations to be performed closer to the point of consultation.

Diagnostic Centers represented an estimated 13.0% market share, valued at approximately USD 0.21 billion in 2025, and are projected to grow at an estimated CAGR of 5.8%. Growth is supported by increasing demand for dedicated diagnostic capacity, outpatient gastrointestinal evaluation, and faster access to lower-GI examinations outside major hospital endoscopy departments.

 

How is the sigmoidoscope market developing across major regions?

North American sigmoidoscope market drivers

North America, particularly the United States, accounts for an estimated 38.0% market share, valued at approximately USD 0.62 billion in 2025, and is projected to grow at an estimated CAGR of 5.2%, supported by a large colorectal screening-eligible population, Medicare coverage, mature gastrointestinal infrastructure, and an active FDA device pathway, while colonoscopy and stool-based testing remain dominant in routine colorectal screening, making targeted lower-GI diagnosis, specialist surveillance, equipment replacement, and outpatient procedure decentralization increasingly important to sigmoidoscope demand.

For example, FDA clearance of LumenEye X1 supports expansion of dedicated digital point-of-care examination systems. For example, Fujifilm's EI-740D/S supports hospitals seeking broader platform utilization across upper- and lower-GI applications.

 

Europe is becoming increasingly focused on capacity and workflow

Europe accounted for an estimated 27.0% market share, valued at approximately USD 0.44 billion in 2025, and is projected to grow at an estimated CAGR of 4.8%. The region has an established endoscopy infrastructure, while England's waiting-list data demonstrate pressure on diagnostic capacity, and flexible sigmoidoscopy activity decreased during 2025 even as waiting lists increased, strengthening demand for more efficient use of endoscopy rooms and outpatient capacity.

For example, the 2025 NHS procurement of LumenEye X1 systems and recurring sheaths shows institutional adoption of a portable lower-GI visualization model. For example, established manufacturers such as Olympus, Fujifilm, and PENTAX Medical continue to compete through broader imaging platforms that allow hospitals to standardize endoscopy equipment across multiple procedures.

 

How Asia-Pacific demand is being shaped by screening and specialist procedures

Asia-Pacific accounted for an estimated 25.0% market share, valued at approximately USD 0.41 billion in 2025, and is projected to grow at an estimated CAGR of 7.0%, with demand varying significantly by healthcare system. Australia relies primarily on stool-based national bowel screening, while clinically indicated sigmoidoscopy remains reimbursed through the MBS. Specialist diagnosis, follow-up examinations, hospital procedure growth, and equipment replacement therefore represent important sources of demand.

For example, Fujifilm maintains an extensive gastrointestinal endoscopy portfolio across Asia-Pacific, supporting hospitals seeking integrated imaging and scope platforms. For example, PENTAX Medical competes through lower-GI endoscopes and imaging systems designed for established gastroenterology departments.

 

Drivers supporting sigmoidoscope demand in Latin America

Latin America accounts for an estimated 6.0% market share, valued at approximately USD 0.10 billion in 2025, and is projected to grow at an estimated CAGR of 5.7%. Demand in the region is concentrated around expanding gastroenterology services, hospital modernization, private diagnostic centers, colorectal specialty care, and the replacement of older endoscopy equipment, with multipurpose platforms being particularly attractive where hospitals need to distribute capital investment across several procedure categories.

For example, global endoscopy manufacturers such as Olympus and Fujifilm compete through broad gastrointestinal portfolios that can support both diagnostic and therapeutic workflows. Growth of private hospital and ambulatory-care infrastructure also creates opportunities for compact systems where faster deployment and lower procedural infrastructure requirements are valued.

 

Drivers of demand across the Middle East and Africa

Demand across the Middle East and Africa is developing around tertiary hospitals, private healthcare expansion, specialist gastroenterology services, colorectal diagnostic programs, and new endoscopy capacity, with the region accounting for an estimated 4.0% market share valued at approximately USD 0.06 billion in 2025 and projected to grow at an estimated CAGR of 5.3%. Hospitals with lower procedure volumes may favor multipurpose endoscopy platforms, while specialist centers can benefit from dedicated or portable systems for focused examinations.

For example, large endoscopy suppliers can leverage imaging processors, scopes, service contracts, and technical-support networks across hospital accounts. For example, portable digital solutions can address facilities seeking additional lower-GI examination capacity without building a complete conventional endoscopy room.

 

How are leading companies positioned in the competitive landscape?

Competition is divided between specialized developers of dedicated sigmoidoscopy systems and major gastrointestinal endoscopy manufacturers that compete through broad scope portfolios, imaging processors, accessories, servicing, and installed equipment bases.

SurgEase Innovations Offering

SurgEase Innovations focuses on digital colorectal visualization through its LumenEye X1 platform. The system combines a reusable endoscope, Full HD tablet display, CHiP software, portable workstation, and procedure-related consumables. Its applications include anorectal assessment, biopsy, colorectal surgery follow-up, anastomosis monitoring, ileal-pouch surveillance, and inflammatory bowel disease assessment.

Its FDA 510(k) clearance and UK institutional procurement support expansion into hospital and outpatient colorectal workflows. The associated sheath model also provides recurring consumable revenue after device installation.

 

Fujifilm’s Offering in the Sigmoidoscope Market

Fujifilm competes through a broad gastrointestinal endoscopy portfolio. The ELUXEO EI-740D/S is a dual-channel gastroscope and sigmoidoscope used for upper- and lower-GI procedures. The scope is supported by Fujifilm's ELUXEO imaging platform, Linked Color Imaging, Blue Light Imaging, processors, peripherals, accessories, and wider colonoscope portfolio.

This integrated portfolio supports hospitals seeking advanced visualization, therapeutic capability, and standardization across multiple gastrointestinal procedures.

 

Olympus gastrointestinal endoscopy portfolio

Olympus competes through its extensive gastrointestinal endoscopy ecosystem. In May 2025, the company announced U.S. FDA 510(k) clearance for its EZ1500 series, including the CF-EZ1500DL/I colonoscope, for use with its EVIS X1 endoscopy system.

Its portfolio includes colonoscopes, imaging processors, visualization technologies, endotherapy devices, cleaning systems, and service infrastructure. The large installed base of broader colonoscopy platforms gives Olympus a competitive position in facilities where distal-colon examinations can be performed using existing lower-GI equipment.

 

PENTAX Medical offers gastrointestinal endoscopy solutions

PENTAX Medical competes through established gastrointestinal imaging and scope platforms. Its lower-GI portfolio includes i10c and i20c colonoscopes, supported by technologies such as iFLEX and TrueTorque and imaging platforms including IMAGINA and INSPIRA.

PENTAX also has historical presence in dedicated video sigmoidoscopy through products such as the ES-3870K. Its wider portfolio allows hospitals to integrate lower-GI visualization with processors, accessories, service support, and broader endoscopy equipment.

 

Analyst Perspective: What factors are likely to shape future sigmoidoscope market growth?

Future market growth will depend on improving the efficiency and cost-effectiveness of lower-GI examinations. Hospitals and clinics are increasingly adopting devices that reduce reliance on full endoscopy suites, speed up procedures, and simplify workflows such as documentation, biopsy, and reprocessing.

Established endoscopy companies benefit from strong installed bases and service networks, while newer digital sigmoidoscope providers compete with portable systems designed for outpatient use and recurring consumable models.

Overall, demand is shifting toward diagnostic and follow-up use cases such as symptomatic lower-GI assessment, IBD surveillance, colorectal surgery follow-up, and outpatient diagnosis. This is further supported by rising procedure backlogs, continued reimbursement coverage, and FDA-cleared digital systems, contributing to the projected USD 2.37 billion market by 2032.

 

Sigmoidoscope Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.62 Billion
Revenue Forecast in 2032	USD 2.37 Billion
Overall Growth Rate	CAGR of 5.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Product Type, By Usage, By Application, By End User, By Geography
By Product Type	Flexible Sigmoidoscopes, Rigid Sigmoidoscopes
By Usage	Reusable Sigmoidoscopes, Disposable Sigmoidoscopes
By Application	Diagnostic, Screening, Therapeutic
By End User	Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Diagnostic Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising demand for targeted lower-GI diagnosis, increasing colorectal disease evaluation, growing outpatient endoscopy adoption, advancement in digital imaging and portable visualization systems, need for improved endoscopy capacity and workflow efficiency
Customization Option	Available upon request